From Amershaminternational Pic, Bucks., U.K. Rosis Or Diffuse Panbronchiolitis

Total Page:16

File Type:pdf, Size:1020Kb

From Amershaminternational Pic, Bucks., U.K. Rosis Or Diffuse Panbronchiolitis VOL. 46 NO. 10 THE JOURNAL OF ANTIBIOTICS 1629 THE EFFECT OF 1^-METHYL AND tive and Gram-negative bacteria. A number of IMIDOYL SUBSTITUENTS ON THE carbapenems, such as olivanic acids3), carpetimy- ANTIPSEUDOMONAL ACTIVITY cins4), asparenomycins5), and others, have been OF CARBAPENEMS discovered. However, none are available for clinical use except imipenem, an 7V-formimidoyl derivative yoshihiro sumita*, yoko eguchi, of thienamycin. Meropenemand panipenem are MasatomoFukasawa, Takao Okuda, new carbapenems under pre-registration in Japan. Hiroshi Yamaga, Haruki Matsumura Meropenem, which differs chemically from imipe- and Makoto Sunagawa nem and panipenem, has a l/?-methyl group and no imidoyl substituent on the 2-sulfur side chain. In Discovery Research Laboratories III, this study, we investigated the antipseudomonal SumitomoPharmaceuticals Research Center, 3-1-98 Kasugade-naka, Konohana, Osaka 554, Japan activity of four series of carbapenems in terms of the structure-activity relationships, especially the (Received for publication June 4, 1993) l/?-methyl and imidoyl moieties. Meropenem and the other carbapenems, sum- Amongthe manyclinical pathogens Pseudomonas marized in Fig. 1, were prepared in Sumitomo aeruginosa is understood as the bacterium that Pharmaceuticals Research Center, Osaka, Japan. causes opportunistic infections in patients under [14C]Benzylpenicillin potassium salt was purchased immunosuppressed conditions or with cystic fib- from AmershamInternational pic, Bucks., U.K. rosis or diffuse panbronchiolitis. It is difficult to VariousP. aeruginosa strains werereference orga- cure P. aeruginosa infections because of its intrinsic nisms stored in our laboratories, and recent clinical resistance to antibiotics1}. Several new /Mactam isolates were obtained from various hospitals in antibiotics with antipseudomonal activity have Japan. The MICs were measured by agar dilution been introduced into clinical therapeutics. Among on Sensitivity Test Agar (Nissui Pharmaceutical, these, carbapenems are of particular interest as Japan), which is modified Mueller-Hinton agar. they have a powerful effect against P. aeruginosa. An overnight culture of the test organism in Sen- The discovery of thienamycin2) created a scientific sitivity Test Broth (Nissui) was diluted in buffered sensation as it has its potent antibacterial activity saline gelatin, and about 104 cfu/spot were inocul- and a wide spectrum of action against Gram-posi- ated onto a drug-containing agar surface. Plates Fig. 1. Chemical structure of carbapenems used in this study. Compound R ± R2 R3 Meropenem CH 3 H Desmethyl meropenem H V/\^<CONMe2 R \ CompoundA CH3 R3 ,I ]j N^CH3 Desmethyl compound A H j NH l jff-Methyl thienamycin CH3 H Thienamycin H \^\ ^R3 ^ l jS-Methyl imipenem CH3 ^ 1 NH Imipenem H J ^^ Compound B CH3 H Desmethyl compound B H ^Y^^) ^ A-n , \/CH3 l Panipenemjg-Methyl panipenemH 3CH3 \R j [fNH Compound C CH3 H Desmethyl compoundC H , . H ( /N~R3 .\/CH3 CompoundD CH3 \ / I |] DesmethylcompoundD H J NH 1630 THE JOURNAL OF ANTIBIOTICS OCT. 1993 Table 1. Antipseudomonal activity of various carbapenem series. MIC (fig/ml) MIC Og/ml) of clinical isolates3 Compound NCTC10490 T IFO3451 PAO2152 TL2666b MIC50 MIC90 Range Meropenem 0.025 0.39 0.39 0.78 0.78 0.55 2.87 0.05-12.5 Desmethyl meropenem 0. 10 12.5 3.13 3.13 6.25 1.92 14.9 0.20- 50 Compound A 0.20 3.13 3.13 3.13 6.25 4.17 18.7 0.39-25 Desmethyl compound A 1.56 25 12.5 12.5 25 14.4 28.1 1.56-50 l jS-Methyl thienamycin 0.78 3.13 1.56 1.56 3.13 1.99 5.26 0.39-12.5 Thienamycin 1.56 6.25 3.13 3.13 6.25 3.23 6.06 0.78-25 l /?-Methyl imipenem 1.56 6.25 1.56 1.56 3.13 2.21 5.83 0.39-12.5 Imipenem 0.78 1.56 1.56 0.78 1.56 0.96 4.42 0.39-12.5 CompoundB 0.20 1.56 1.56 1.56 1.56 1.19 4.05 0.20- 6.25 Desmethyl compound 1.56 3.13 1.56 1.56 3.13 1.51 4.82 0.39-25 1.56 25 6.25 12.5 12.5 13.5 23.1 0.39-50 Panipeneml /?-Methyl panipenem 1.56 12.5 3.13 3.13 6.25 4.42 ll.9 0.39-25 CompoundC 0.39 12.5 1.56 3.13 6.25 4.58 10.1 0.39- 12.5 Desmethyl compoundC 0.78 12.5 3.13 6.25 6.25 6.01 14.0 0.39-25 CompoundD 0.78 25 3.13 12.5 6.25 13.5 22.1 0.20-25 Desmethyl compoundD 0.78 12.5 3.13 6.25 6.25 9.32 21.0 0.20-50 a /i=25. b Typical clinical isolate. were incubated at 37°C for 18hours. The MICwas tophilia IID127311} by the method of Satno12). defined as the lowest concentration that completely Table 1 shows the antipseudomonal activities of inhibited visible growth. MIC5Os and MIC90s were various carbapenems. Weused 4 standard labora- calculated from the equation describing the linear tory strains and 26 clinical isolates of P. aeruginosa. part of the curve. Of 16 carbapenems used in this study meropenem P. aeruginosa cell membraneswere prepared as was most the active one against P. aeruginosa, previously described6). P. aeruginosa grown to followed by imipenem and compound B. In all four late-exponential phase was harvested, and the cells carbapenemseries, the introduction of a l/?-methyl were ruptured by sonication. The membrane substituent to compounds having an imidoyl group fractions were pelleted by ultracentrifugation. The reduced the antipseudomonal activity, whereas affinities of the carbapenems for penicillin-binding ljft-methyl compounds without an imidoyl moiety proteins (PBPs) were determined by means of a were more active than their corresponding des- competition assay using [14C]benzylpenicillin, methyl derivatives. There may be some congeniality essentially as previously described6'"0. We used among l/?-methyl and imidoyl substituents on P. aeruginosa NCTC1 0490 because this strain always antibacterial activity against P. aeruginosa. How- produces very sharp and clear PBP bands on ever, desmethyl compoundA was much less active sodium dodecyl sulfate-polyacrylamide gel electro- than compoundA. This may be because the bulky phoresis (SDS-PAGE). Meropenem and imipenem side chains in compoundA, acetimidoyl and di- show the same binding profiles to PBPs in three methylcarbamoyl groups on the pyrrolidine moiety, strains of P. aeruginosa.6) Therefore, this result interfere with its ownbinding to the target PBPs. could be generalized for all susceptible P. aerugi- The antibacterial activity of carbapenems greatly nosa. depends on their affinity and access to targets The permeability of carbapenems through the (PBPs) of P. aeruginosa. We selected, therefore, outer membraneof P. aeruginosa was measured meropenemand imipenem series of carbapenems using /Mactamaseenclosed proteoliposome recon- as representatives and examined their affinity for stitution assays8'9). The outer membrane was PBPs and the permeation through the outer mem- purified from P. aeruginosa PAO2152 by the brane using proteoliposomes containing L-l /?- procedure previously described10). The L-l type lactamase. The affinities of four carbapenems are /Mactamase was purified from Xanthomonasmal- summarized in Table 2. Meropenemhad higher VOL. 46 NO. 10 THE JOURNAL OF ANTIBIOTICS 1631 Table 2. Affinities of the series of meropenem and imipenem for PBPs in Pseudomonas aeruginosa NCTC10490a. IC50 Cg/ml)" Antibiotic 3 4 5 Meropenem 0.96 0.84 0.13 0.060 0.022 >10 Desmethyl meropenem 0.49 2.6 0.87 0.38 0.054 >10 1 /MViethyl imipenem 1.7 3.2 0.49 0.94 0.018 >10 Imipenem 0.40 0.81 0.23 0.53 0.014 4.6 Membranefractions were incubated with carbapenems at various concentrations for 10 minutes at 30°C. Subsequently, [14C]benzylpenicillin was added and the incubation was continued for another 10 minutes. Reactions were terminated by adding excess non-radioactive benzylpenicillin and sarkosyl. [ 1 4C]Benzylpenicillin- protein complexes were resolved by SDS-PAGE,followed by fluorography. Values indicate concentrations of antibiotics required to reduce [14C]benzylpenicillin binding by 50%. affinities than desmethyl meropenem, for all PBPs Pharmaceutical University, for valuable suggestions on except PBP1A. Conversely, 1^-methyl imipenem permeability studies in vesicles containing /Mactamase. had less affinity than imipenem. Wealso acknowledge the excellent technical assistance of The relative outer membrane permeability of Yuko Shiono and Yasuko Hirai. meropenem, desmethyl meropenem, 1^-methyl imipenem and imipenem were 100, 110+28, 167+ References 25 and 207+44, respectively, assays performed in 1) Quinn, J. P.: Intrinsic antibiotic resistance in triplicate. The permeation of meropenem and Pseudomonas aeruginosa. In Pseudomonas, Mole- desmethyl meropenemthrough the outer membrane cular Biology and Biotechnology. Ed., E. Calli was lower than that of l/?-methyl imipenem and et aL, pp. 154-160, American Society for Micro- imipenem.However,meropenemwas most active biology, 1992 against P. aeruginosa. These results indicate that 2) Kahan, J. S.; F. M. Kahan, R. Goegelman, S. A. the antipseudomonal activity of these four carba- Currie, M. Jackson, E. O. Stapley, T. W. Miller, penems was directly reflected in their affinity for A. K. Miller, D. Hendlin, S. Mochales, S. PBPs but not related to outer membrane perme- Hernandez, H. B. Woodruff & J. Birnbaum: Thienamycin, a new /Mactam antibiotic. I. Disco- ability. With or without the l/?-methyl moiety, very, taxonomy, isolation and physical properties. meropenemand imipenem series showed almost J. Antibiotics 32: 1-12, 1979 the same permeability rate through the outer mem- 3) Brown, A. G.; D. F. Corbett, A. J. Eglington brane of P. aeruginosa. The permeability of carba- & T. T. Howarth: Structures of olivanic acid penem seemed to depend on the structure of their derivatives MM 22380, MM 22381, MM 22382 and 2-side chain.
Recommended publications
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Revision of Precautions
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Cefmenoxime hydrochloride (preparations for otic and nasal use), chloramphenicol (solution for topical use, oral dosage form), tetracycline hydrochloride (powders, capsules), polymixin B sulfate (powders), clindamycin hydrochloride, clindamycin phosphate (injections), benzylpenicillin potassium, benzylpenicillin benzathine hydrate, lincomycin hydrochloride hydrate, aztreonam, amoxicillin hydrate, ampicillin hydrate, ampicillin sodium, potassium clavulanate/amoxicillin hydrate, dibekacin sulfate (injections), sultamicillin tosilate hydrate, cefaclor, cefazolin sodium, cefazolin sodium hydrate, cephalexin (oral dosage form with indications for otitis media), cefalotin sodium, cefixime hydrate, cefepime dihydrochloride hydrate, cefozopran hydrochloride, cefotiam hydrochloride (intravenous injections), cefcapene pivoxil hydrochloride hydrate, cefditoren pivoxil, cefdinir, ceftazidime hydrate, cefteram pivoxil, ceftriaxone sodium hydrate, cefpodoxime proxetil, cefroxadine hydrate, cefuroxime axetil, tebipenem pivoxil, doripenem hydrate, bacampicillin hydrochloride, panipenem/betamipron, faropenem sodium hydrate, flomoxef sodium, fosfomycin calcium hydrate, meropenem hydrate, chloramphenicol sodium succinate,
    [Show full text]
  • Pharmacokinetics of Penicillin G in Preterm and Term Neonates
    AAC Accepted Manuscript Posted Online 20 February 2018 Antimicrob. Agents Chemother. doi:10.1128/AAC.02238-17 Copyright © 2018 American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics of penicillin G in preterm and term neonates 2 Helgi Padari1, Tuuli Metsvaht1, Eva Germovsek2, Charlotte I Barker2,3, Karin Kipper3,4, Koit 3 Herodes4, Joseph F Standing2, Kersti Oselin5, Tõnis Tasa6, Hiie Soeorg7#, Irja Lutsar7 4 Downloaded from 5 1Pediatric Intensive Care Unit, Tartu University Hospital, Tartu, Estonia 6 2UCL Great Ormond Street Institute of Child Health, University College London, London, 7 UK 8 3Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St http://aac.asm.org/ 9 George’s University of London, London, UK 10 4Institute of Chemistry, University of Tartu, Estonia 11 5Clinic of Haematology and Oncology, North Estonia Medical Centre, Tallinn, Estonia 6 12 Institute of Computer Science, University of Tartu, Estonia on March 9, 2018 by UC London Library Services 13 7Department of Microbiology, University of Tartu, Tartu, Estonia 14 15 #Corresponding author: Hiie Soeorg; e-mail address: [email protected] 16 17 Running title: Pharmacokinetics of penicillin G in neonates 1 18 Abstract 19 Group B streptococci are common causative agents of early-onset neonatal sepsis (EOS). 20 Pharmacokinetic (PK) data for penicillin G have been described for extremely preterm 21 neonates but poorly for late-preterm and term neonates. Thus, evidence-based dosing Downloaded from 22 recommendations are lacking. We described PK of penicillin G in neonates with gestational 23 age (GA) ≥32 weeks and postnatal age <72 h. Penicillin G was administered intravenously at 24 a dose of 25,000 or 50,000 IU/kg/q12h.
    [Show full text]
  • Synergy of Fosfomycin with Other Antibiotics for Gram-Positive and Gram-Negative Bacteria Antonia C
    Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria Antonia C. Kastoris, Petros I. Rafailidis, Evridiki K. Vouloumanou, Ioannis D. Gkegkes, Matthew E. Falagas To cite this version: Antonia C. Kastoris, Petros I. Rafailidis, Evridiki K. Vouloumanou, Ioannis D. Gkegkes, Matthew E. Falagas. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. European Journal of Clinical Pharmacology, Springer Verlag, 2010, 66 (4), pp.359-368. 10.1007/s00228-010-0794-5. hal-00570019 HAL Id: hal-00570019 https://hal.archives-ouvertes.fr/hal-00570019 Submitted on 26 Feb 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2010) 66:359–368 DOI 10.1007/s00228-010-0794-5 PHARMACODYNAMICS Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria Antonia C. Kastoris & Petros I. Rafailidis & Evridiki K. Vouloumanou & Ioannis D. Gkegkes & Matthew E. Falagas Received: 24 August 2009 /Accepted: 26 January 2010 /Published online: 26 February 2010 # Springer-Verlag 2010 Abstract with other antibiotics. Yet, in the 27 studies providing data for Background The alarming increase in drug resistance and Gram-positive strains (16 for Staphylococcus aureus, 3 for decreased production of new antibiotics necessitate the coagulase-negative staphylococci, 5 for Streptococcus evaluation of combinations of existing antibiotics.
    [Show full text]
  • Case of a Cerebral Abscess Caused by Porphyromonas Gingivalis in A
    BMJ Case Reports: first published as 10.1136/bcr-2016-218845 on 22 February 2017. Downloaded from Rare disease CASE REPORT Case of a cerebral abscess caused by Porphyromonas gingivalis in a subject with periodontitis Frederic Van der Cruyssen, Koenraad Grisar, Honorine Maes, Constantinus Politis OMFS-IMPATH Research SUMMARY related cases. Well-accepted reviews served as the Group, Department of Imaging We report the case of a 65-year-old man presenting foundation for this article. Additional original arti- and Pathology, Faculty of Medicine, Catholic University with generalised seizures after developing a right frontal cles were selected by reading the abstract and Leuven, Leuven, Belgium brain abscess. Stereotactic aspiration and subsequent obtaining the full text when needed. Search terms matrix assisted laser desorption/ionisation time-of-flight included: brain abscess, cerebral abscess, P. gingiva- Correspondence to analyzer (MALDI-TOF) spectrometry revealed lis, odontogenic, periodontitis, parodontitis, tooth Dr Frederic Van der Cruyssen, Porphyromonas gingivalis as the only causative anaerobe infection and oral pathogen. Five articles were frederic.vandercruyssen@ uzleuven.be microorganism. Secondary incision and drainage was selected that discussed intracranial abscess forma- required due to neurological deterioration with increased tion by P. gingivalis. Accepted 10 February 2017 dimensions of the abscess, intracranial pressure and formation of a subdural occipitoparietal empyema. Oral CASE PRESENTATION imaging was positive for apical periodontitis of multiple We report the case of a 65-year-old man with a elements; therefore, the remaining dentition was medical history of prostate carcinoma, for which he removed. Targeted antibiotic treatment included underwent radical prostatectomy with adjuvant intravenous ceftriaxone and ornidazole.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0150995 A1 Taft, III Et Al
    US 2015O150995A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0150995 A1 Taft, III et al. (43) Pub. Date: Jun. 4, 2015 (54) CONJUGATED ANTI-MICROBIAL Publication Classification COMPOUNDS AND CONUGATED ANT-CANCER COMPOUNDS AND USES (51) Int. Cl. THEREOF A647/48 (2006.01) A63/546 (2006.01) (71) Applicant: PONO CORPORATION, Honolulu, HI A633/38 (2006.01) (US) (52) U.S. Cl. CPC ........... A61K47/480.15 (2013.01); A61K33/38 (72) Inventors: Karl Milton Taft, III, Honolulu, HI (2013.01); A61 K3I/546 (2013.01) (US); Jarred Roy Engelking, Honolulu, HI (US) (57) ABSTRACT (73) Assignee: PONO CORPORATION, Honolulu, HI Disclosed herein are synthesis methods for generation of (US) conjugated anti-microbial compounds and conjugated anti cancer compounds. Several embodiments, related to the uses (21) Appl.ppl. NNo.: 14/418,9079 of Such compoundsp in the treatment of infections, in particu lar those caused by drug-resistant bacteria. Some embodi (22) PCT Filed: Aug. 9, 2013 ments relate to targeting cancer based on the metabolic sig (86). PCT No.: PCT/US2O13/O54391 nature of tumor cells. S371 (c)(1), (2) Date: Jan. 30, 2015 NH Related U.S. Application Data O Ag" (60) Provisional application No. 61/742,443, filed on Aug. B-Lactam Silver Ion 9, 2012, provisional application No. 61/742,444, filed on Aug. 9, 2012. O O O O O O HSONaNO -pE (CHO)2SO2 OEt Br2 OEt 2W4 OH NOMe 1 2 3 Q Q H.N.S NH, NHT chicci -VV653C(CH) NaOH Bra-oe 2 2 S1N (C6H5)3C- SNN a NOMe MeO -co.
    [Show full text]
  • Author Section
    AUTHOR SECTION patients with new onset of fever, demographic, clinical, and laborato- Mycoplasma spp. Overall, the spectrum of antibacterial activity indi- ry variables were obtained during the 2 days after inclusion, while cates a potential role for this combination in the treatment of diffi- microbiological results for a follow-up period of 7 days were collect- cult-to-treat Gram-positive infections, including those caused by ed. Patients were followed up for survival or death, up to a maximum multidrug-resistant organisms. Since this activity extends to Gram- of 28 days after inclusion. MEASUREMENTS AND RESULTS: Of negative respiratory bacteria, quinupristin/dalfopristin may also find all patients, 95% had SIRS, 44% had sepsis with a microbiologically a role in the treatment of atypical, as well as typical, pneumonia. confirmed infection, and 9% died. A model with a set of variables all significantly (p<0.01) contributing to the prediction of mortality was Boubaker A. et al. [Investigation of the urinary tract in children in nuclear med- derived.The set included the presence of hospital-acquired fever, the icine]. Rev Med Suisse Romande. 2000; 120(3) : 251-7.p Abstract: peak respiratory rate, the nadir score on the Glasgow coma scale, and The early detection of urologic abnormalities by antenatal sonogra- the nadir albumin plasma level within the first 2 days after inclusion. phy has resulted in the investigation of many infants and neonates for This set of variables predicted mortality for febrile patients with suspicion of either obstructive uropathy or reflux nephropathy. microbiologically confirmed infection even better.The predictive val- Nuclear medicine techniques allow to assess renal parenchyma ues for mortality of SIRS and sepsis were less than that of our set of integrity, to detect pyelonephritic scars and to measure absolute and variables.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]